Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
61
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy

Mostafa Yakoot1 Green Clinical Research Center;2 Abbas Helmy ClinicsCorrespondence[email protected]
,
Alaa M Abdo3 Tropical Medicine and Hepatology Department, Alexandria Faculty of Medicine
,
Ahmed Yousry4 Microbiology Department, High Institute of Public Health, Alexandria University;5 Mabarat Asafra Labs
&
Sherine Helmy6 Pharco Corporation, Alexandria, Egypt
Pages 2659-2667 | Published online: 25 Aug 2016

References

  • LavanchyDEvolving epidemiology of hepatitis C virusClin Microbiol Infect201117210711521091831
  • GuerraJGarenneMMohamedMKFontanetAHCV burden of infection in Egypt: results from a nationwide surveyJ Viral Hepat201219856056722762140
  • SchinaziRHalfonPMarcellinPAsselahTHCV direct-acting antiviral agents: the best interferon-free combinationsLiver Int201434Suppl 1697824373081
  • FerenciPLaferlHScherzerTMAustrian Hepatitis Study GroupPeginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological responseGastroenterology2008135245145818503773
  • HoofnagleJHWahedASBrownRSJrHowellCDBelleSHVirahep-C Study GroupEarly changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infectionJ Infect Dis200919981112112019284286
  • EsmatGEAl AkelWAbdel AzizRAHepatitis C viral kinetic changes in a retrospective cohort study of chronic hepatitis C virus Egyptian patients on pegylated interferon and ribavirin therapyJ Interferon Cytokine Res201636314915826982165
  • MaasoumyBVermehrenJWelkerMWClinical value of on-treatment HCV RNA levels during different approved sofosbuvir-based antiviral regimensJ Hepatol Epub2016413
  • KohliAKattakuzhySSidharthanSFour-week direct-acting antiviral regimens in non-cirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trialAnn Intern Med20151631289990726595450
  • DossWShihaGHassanyMSofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4J Hepatol201563358158525937436
  • YakootMAbdoAMYousryAHelmySThe very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness studyDrug Des Devel Ther2015960276033
  • WedemeyerHJensenDMGodofskyEManiNPawlotskyJMMillerVDefinitions/Nomenclature Working Group of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV ResearchRecommendations for standard-ized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agentsHepatology20125662398240322707382
  • AASLD/IDSA HCV Guidance PanelHepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology201562393295426111063
  • DahariHCaniniLGrawFHCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvirJ Hepatol20166461232123926907973
  • RuanePJAinDStrykerRSofosbuvir plus ribavirin for the treatment of chronic genotype four hepatitis C virus infection in patients of Egyptian ancestryJ Hepatol20156251040104625450208

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.